AI generated
Sep 24, 2026, 14:33
Mohamed El Belghiti Alaoui: Thrombin as a Therapeutic Target in Coagulation
Mohamed El Belghiti Alaoui, Independent Researcher, shared a post on LinkedIn:
“Thrombin-catalyzed cleavage of fibrinogen into fibrin.
Consider how thrombin’s conversion of fibrinogen into fibrin safeguards you, guides tissue repair, and defines therapeutic targets.
This clotting cascade instantly forms a stable mesh that stops bleeding, supports platelet attachment for healing, and balances coagulation to prevent thrombosis or hemorrhage.
- Creates insoluble fibrin mesh, sealing vascular injury and preventing dangerous blood loss.
- Provides structural framework for platelet adhesion and wound healing, supporting tissue regeneration.
- Thrombin overactivity triggers pathological clotting, while deficiency causes hemorrhage-making it a key anticoagulant drug target.
How do you see modulating thrombin activity influencing patient outcomes?”
Stay updated with Hemostasis Today.
-
Sep 24, 2026, 14:22Integrating Thrombosis Risk Into Menopause Care – World Thrombosis Day
-
Sep 24, 2026, 13:41Mahmoud Samir Bayomi: Raise ITP Awareness and Improve Patient Care
-
Sep 24, 2026, 12:56Maria Helena Parrinello: A New Score for Chronic GvHD Risk Assessment at the SIE Congress
-
Sep 24, 2026, 12:44Shehab Mohamed: TP53 Mutations and Outcomes in Myeloproliferative Neoplasms
-
Sep 24, 2026, 12:34Francesca Palandri: Is There Still a Place for Splenectomy in ITP in the Modern Era?
-
Sep 24, 2026, 12:15Cedric Hermans: RPTH Illustrated Review on Von Willebrand Disease
-
Sep 24, 2026, 11:48Factor XII Inhibition and the Future of Contact Pathway Targeting
-
Sep 24, 2026, 08:55Andres Gudino: Clot Characterization Through Hounsfield Units in Ischemic Stroke
-
Sep 24, 2026, 06:52Gina Sado: Screening-Detected Atrial Fibrillation Carries High Risk of Heart Failure